StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Protagonist Therapeutics's EV/EBITDA was 132.6× on Nov 11, 2026, against 84.3× a year earlier. Over the last 2 years it ranged from 7.4× to 251.8×, with a median of 84.3×.

EV/EBITDA at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026132.6×−111.0
2025Dec 31, 2025243.5×+231.4
2024Dec 31, 202412.2×–

More Protagonist Therapeutics figures

See a number that looks wrong?